"Forever Iron Man, Professor Zhou Jianfeng, a big coffee in Clinical Research at CAR-TI in China, has gone all the way." Many domestic hematology experts, relevant scientific researchers and patients have remembered and recalled "Professor Zhou" on social platforms.
Edit | Huang Xiaohuang
Source| Fujian Health News
Professor Zhou Jianfeng, chairman of the Hematology and Tumor Committee of the Chinese Anti-Cancer Association and director of the Department of Hematology of Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, left us forever at 11:37 on March 27, 2022 due to sudden rupture of coronary artery dissection and ineffective rescue.
Zhou Jianfeng, former director of the Department of Hematology (national key discipline, national clinical key specialty) of Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, deputy director of the Tumor Biomedical Center of Tongji Hospital of the Key Laboratory of the Ministry of Education, member of the Blood Branch of the Chinese Medical Association, deputy leader of the Experimental Diagnostics Group, member of the Chinese Experimental Hematology Society, and member of the Standing Committee of the Blood Branch of the Chinese Anti-Cancer Association. He is a top coffee in the field of hematology and oncology in China, a leader in CAR-T treatment, a recipient of the National Outstanding Youth Fund, and has been engaged in clinical work in hematology for 25 years.
"Forever Iron Man, Professor Zhou Jianfeng, a big coffee in Clinical Research at CAR-TI in China, has gone all the way." "I'm sorry, Professor Zhou, I won't have a chance to send you a bigger pennant in the future." "This time, he can finally rest." Many domestic hematology experts, relevant scientific researchers and patients have remembered and recalled "Professor Zhou" on social platforms.
He is a teacher and role model for many medical workers in the field of blood;
He is the light of hope for the lives of countless patients;
He is a leader in the field of immune cell therapy in China and even in the world;
He is a pioneer in domestic CAR-T treatment....
Just a while ago, he also participated in several academic conferences, gave a number of wonderful lectures, and completed the diagnosis and treatment consultation of many patients. For the sake of the doctor, forget yourself. Despite being overwhelmed, he was still concerned about the health of his patients and the development of the field, and fought to the last moment of his life.
Professor Zhou Jianfeng is low-key and peaceful, gentle and elegant, does not hesitate to teach and promote the younger generations, loves life and loves food. In an interview, he once said: "No matter how busy and tired you are, when you see your patient, a patient who was once desperate, come back to life after full treatment, you will feel that all the efforts are worth it." For a doctor, I think this is the most touching moment. It is this kind of touching that inspires himself and his team, no matter how difficult it is, to continue to heal, to help, to climb the peak of medicine."
"I am confident in CAR-T's prospects in China"
On September 3, 2021, the mainland's first Class 1 biological new drug CAR-T product Reggio Ollensay was officially approved for clinical use, and on the day of listing, Professor Zhou Jianfeng issued the first prescription for patients in China.
"The first patient to receive domestic CAR-T treatment, Big Bear (pseudonym), suffered from double-blow diffuse large B-cell lymphoma, which was more malignant, and the survival rate of treatment with existing chemotherapy methods may only be 20%-30%."
"This is the closest level of anti-cancer drugs in mainland China to the world."
Zhou Jianfeng believes that CAR-T therapy will be a milestone breakthrough in the field of tumor treatment, which miraculously "cured" many cancer patients and changed the fate of patients. He is full of confidence in the prospects of clinical application of CAR-T in China.
At this year's Second China Hematology Development Conference, the Top Ten Research Progresses of Chinese Hematology in 2021 were released. Professor Zhou Jianfeng's team at Tongji Hospital of Huazhong University of Science and Technology won the honor for "a series of studies on the application of fully human anti-BCMA CAR (CT103A) in the treatment of relapsed/refractory multiple myeloma".
Compared with the previous murine-derived single-chain antibody CAR-T treatment method, the all-human CAR-T therapy used by Zhou Jianfeng's team greatly reduces disease recurrence, has good efficacy and higher safety, and will enter the first-line clinical trial from clinical trials in the future to benefit more myeloma patients.
Professor Zhou Jianfeng once explained the CAR-T treatment method in popular terms: CAR-T treatment is to change T cells from an ordinary warrior who turns a blind eye to tumor cells, and through armament, he can not only find tumor cells but also destroy tumor cells in time, and exist in the body for a long time. CAR-T treatment is to collect and isolate T cells from the blood of cancer patients, and then genetically modified in vitro to install "recognizers" on T cells so that they can quickly identify tumor cells. At the same time, genetic modification will also give T cells an activation signal, so that it is like a cannonball with leads, as long as it encounters tumor cells, it will "explode" and "blow up" tumor cells.
CAR-T treatment research has been conducted for 30 years. Over the past 30 years, through the joint efforts of scientists and doctors, CAR-T treatment has changed from a theory to a clinical drug, unveiling a new era of live-cell cancer treatment. Completely different from the previous treatment of cancer, it is a "live" drug, it will always be present in the body, even in patients who received CAR-T treatment 10 years ago, the body examination can still detect the ingredients.
At the same time, different CAR-T treatment drugs can treat different tumors. At present, CAR-T treatment drugs are mainly used to treat lymphoma, leukemia, multiple myeloma, however, Professor Zhou Jianfeng believes that this is just a prelude, CAR-T treatment is a vast ocean, the future is expected to treat almost all diseases in the blood disease, including the treatment of solid tumors, is also being studied, I believe that CAR-T treatment can treat more and more diseases in the future. For some cancer patients, CAR-T treatment can indeed achieve the miraculous effect of clearing cancer cells. Unlike traditional chemoradiation and repeated hospital treatment of cancer, CAR-T treatment is a one-time treatment.
Professor Zhou Jianfeng, all the way! (Original title: Grief!) Professor Zhou Jianfeng, a famous hematologist, died at the age of 57)
END
The 2022 National Hospital Operation Conference is coming!
From "large-scale construction" to "fine operation", how to establish a modern hospital management system? How to achieve refined, high-quality and leapfrog development of medical institutions through benign operation? How to build a market-recognized brand ?.... On May 28-29, the 2022 National Hospital Operation Conference sponsored by the 2022 Shanghai Medical Fair Expert Committee, the Institute of Social Medical Institutions of Shanghai Jiaotong University, and the medical media will be held in Shanghai.